Reshaping the HIV treatment and prevention landscape

Gepotidacin: Potential first-in-class oral antibiotic targeting antibiotic resistance High unmet need for novel oral 2nd line antibiotics due to rising resistance & safety concerns¹ 8% 11% 19% 62% No known resistance Resistant to 1 antibiotic Resistant to 2 antibiotics Resistant to 3+ antibiotics ~15m uUTIs per year in US 38% are resistant to 1 or more antibiotics Powerful alternative to counter resistance - - - Increasing resistance to 1L antibiotics drives urgent need 2L broad-spectrum fluoroquinolones risk serious side effects and resistance, yet have 25% share of market² Convenient novel oral option presents £0.5-1bn opportunity Gepotidacin potential to deliver new antibiotic option: - - - - Novel mechanism of action (triazaacenaphthylene topoisomerase inhibitor) Active in vitro against most antibiotic-resistant uropathogens including E. coli; S. saprophyticus No known cross-resistance 2x daily oral dosing, short course (5 days uUTI) Phase 3 study results expected 20223 1. GSK US physician market research, 2019. 2. IQVIA Claims and LRX Databases, MAT February 2020. Data reported is projected for US episodes. 3. interim analysis subject to regulators feedback In partnership with the US government's Biomedical Advanced Research and Development Authority and Defense Threat Reduction Agency-funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OTA number HHSO100201300011C. gsk 87

View entire presentation